KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Non-Current Deffered Revenue (2018 - 2023)

Historic Non-Current Deffered Revenue for Astrazeneca (AZN) over the last 6 years, with Q4 2023 value amounting to $7.0 million.

  • Astrazeneca's Non-Current Deffered Revenue fell 5000.0% to $7.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $7.0 million, marking a year-over-year decrease of 5000.0%. This contributed to the annual value of $7.0 million for FY2023, which is 5000.0% down from last year.
  • As of Q4 2023, Astrazeneca's Non-Current Deffered Revenue stood at $7.0 million, which was down 5000.0% from $14.0 million recorded in Q4 2022.
  • Astrazeneca's 5-year Non-Current Deffered Revenue high stood at $50.0 million for Q4 2019, and its period low was $7.0 million during Q4 2023.
  • For the 5-year period, Astrazeneca's Non-Current Deffered Revenue averaged around $27.0 million, with its median value being $26.0 million (2021).
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first tumbled by 2400.0% in 2020, then plummeted by 5000.0% in 2023.
  • Quarter analysis of 5 years shows Astrazeneca's Non-Current Deffered Revenue stood at $50.0 million in 2019, then decreased by 24.0% to $38.0 million in 2020, then plummeted by 31.58% to $26.0 million in 2021, then crashed by 46.15% to $14.0 million in 2022, then tumbled by 50.0% to $7.0 million in 2023.
  • Its last three reported values are $7.0 million in Q4 2023, $14.0 million for Q4 2022, and $26.0 million during Q4 2021.